CD30 +
About
Biomarker type: Protein expression
Marker: CD30
Unit: status
Equality: =
Value: Positive
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) | CD30 + | Anaplastic Large Cell Lymphoma | Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone | |
| FDA (1) | CD30 + | Anaplastic Large Cell Lymphoma | Brentuximab vedotin | |
| EMA (1) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin, Dacarbazine, Doxorubicin, Vinblastine | |
| EMA (2) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin | |
| EMA (1) | CD30 + | Cutaneous T-cell Lymphoma | Brentuximab vedotin | |
| EMA (1) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin, Cyclophosphamide, Dacarbazine, Dexamethasone, Doxorubicin, Etoposide |